Marco Di Carlo1,2, Andrea Becciolini3,4, Valentina Lato3,4, Chiara Crotti3,4, Ennio Giulio Favalli3,4, Fausto Salaffi3,4. 1. From the Rheumatology Department, Polytechnic University of Marche, Jesi; Rheumatology Department, Istituto Ortopedico Gaetano Pini, Milan; Clinical and Community Sciences Department, University of Milan, Milan, Italy. dica.marco@yahoo.it. 2. M. Di Carlo, MD, Rheumatology Department, Polytechnic University of Marche; A. Becciolini, MD, Rheumatology Department, Istituto Ortopedico Gaetano Pini; V. Lato, MD, Rheumatology Department, Polytechnic University of Marche; C. Crotti, MD, Clinical and Community Sciences Department, University of Milan; E.G. Favalli, MD, Rheumatology Department, Istituto Ortopedico Gaetano Pini; F. Salaffi, MD, PhD, Rheumatology Department, Polytechnic University of Marche. dica.marco@yahoo.it. 3. From the Rheumatology Department, Polytechnic University of Marche, Jesi; Rheumatology Department, Istituto Ortopedico Gaetano Pini, Milan; Clinical and Community Sciences Department, University of Milan, Milan, Italy. 4. M. Di Carlo, MD, Rheumatology Department, Polytechnic University of Marche; A. Becciolini, MD, Rheumatology Department, Istituto Ortopedico Gaetano Pini; V. Lato, MD, Rheumatology Department, Polytechnic University of Marche; C. Crotti, MD, Clinical and Community Sciences Department, University of Milan; E.G. Favalli, MD, Rheumatology Department, Istituto Ortopedico Gaetano Pini; F. Salaffi, MD, PhD, Rheumatology Department, Polytechnic University of Marche.
Abstract
OBJECTIVE: To study, in a real-life setting, the construct validity, the reliability, and the interpretability of the 12-item Psoriatic Arthritis Impact of Disease (PsAID-12) questionnaire in patients with psoriatic arthritis (PsA). METHODS: In 144 consecutive patients with PsA (81 men and 63 women, mean age of 51.4 ± 12.8 yrs, and 77 receiving biologic treatment), the PsAID-12 and other patient-reported outcomes (PRO) were collected, such as the Dermatology Life Quality Index. Each patient underwent articular and skin assessment. RESULTS: Construct validity: Factor analysis revealed a 2-factor result defined as the PsAID Symptom Score and the PsAID Skin Score. In determining convergent validity, significant correlations were found between the PsAID-12 and the clinical Disease Activity index for Psoriatic Arthritis (cDAPSA; ρ = 0.867, p < 0.0001). Multivariable analysis showed that the PsAID-12 is determined by the articular disease activity (cDAPSA, p < 0.0001), severity of psoriasis (PsO; physician's global assessment, p < 0.0001), and the presence of a coexisting fibromyalgia (FM; p < 0.0001). Reliability: Cronbach's alpha coefficient was 0.93 for the total PsAID-12. Interpretability: Applying the cDAPSA categorization of disease activity states, the PsAID-12 cutoff values resulted in 1.4 between remission and low disease activity (LDA), 4.1 between LDA and moderate disease activity (MDA), and 6.7 between MDA and high disease activity. CONCLUSION: The PsAID-12 is an excellent PRO to evaluate the effect of PsA. It should be carefully handled in patients with coexisting FM.
OBJECTIVE: To study, in a real-life setting, the construct validity, the reliability, and the interpretability of the 12-item Psoriatic Arthritis Impact of Disease (PsAID-12) questionnaire in patients with psoriatic arthritis (PsA). METHODS: In 144 consecutive patients with PsA (81 men and 63 women, mean age of 51.4 ± 12.8 yrs, and 77 receiving biologic treatment), the PsAID-12 and other patient-reported outcomes (PRO) were collected, such as the Dermatology Life Quality Index. Each patient underwent articular and skin assessment. RESULTS:Construct validity: Factor analysis revealed a 2-factor result defined as the PsAID Symptom Score and the PsAID Skin Score. In determining convergent validity, significant correlations were found between the PsAID-12 and the clinical Disease Activity index for Psoriatic Arthritis (cDAPSA; ρ = 0.867, p < 0.0001). Multivariable analysis showed that the PsAID-12 is determined by the articular disease activity (cDAPSA, p < 0.0001), severity of psoriasis (PsO; physician's global assessment, p < 0.0001), and the presence of a coexisting fibromyalgia (FM; p < 0.0001). Reliability: Cronbach's alpha coefficient was 0.93 for the total PsAID-12. Interpretability: Applying the cDAPSA categorization of disease activity states, the PsAID-12 cutoff values resulted in 1.4 between remission and low disease activity (LDA), 4.1 between LDA and moderate disease activity (MDA), and 6.7 between MDA and high disease activity. CONCLUSION: The PsAID-12 is an excellent PRO to evaluate the effect of PsA. It should be carefully handled in patients with coexisting FM.
Authors: Ana-Maria Orbai; Richard Holland; Ying Ying Leung; William Tillett; Niti Goel; Robin Christensen; Neil McHugh; Laure Gossec; Maarten de Wit; Pil Højgaard; Laura C Coates; Philip J Mease; Julie Birt; Lara Fallon; Oliver FitzGerald; Alexis Ogdie; Beverly Shea; Vibeke Strand; Kristina Callis Duffin; Peter Tugwell; Dorcas Beaton; Dafna D Gladman Journal: J Rheumatol Date: 2018-12-15 Impact factor: 4.666